Who
Jula Inrig
EVP, Head of R&D & CMO
Company insider
Files Form 4 as: EVP, Head of R&D & CMO, Travere Therapeutics.
In numbers
- Trades disclosed
- 79
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $10.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jan 2022
- Last trade
- 15 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $289K32,395 at $8.93 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M25,390 at $62.02 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M17,284 at $62.62 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,395 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $102K1,600 at $63.69 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K400 at $65.31 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —32,395 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $289K32,395 at $8.93 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.6M25,390 at $62.02 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M17,284 at $62.62 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $102K1,600 at $63.69 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K400 at $65.31 | filing |
| 22 Jun 2026filed 22 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code G | —468 at $0.00 | filing |
| 22 Jun 2026filed 22 Jun 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code G | —468 at $0.00 | filing |
| 6 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K311 at $43.95 | filing |
| 6 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K311 at $43.95 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $101K2,174 at $46.65 | filing |
| 5 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $101K2,174 at $46.65 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $448K20,000 at $22.40 | filing |
| 4 May 2026filed 6 May 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $900K20,000 at $45.00 | filing |
News
Travere (NASDAQ: TVTX) CEO sells 243,735 shares after option exercisesTVTX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Jula Inrig; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.